![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter
Treatment of Renal Cancer
The therapy of renal-cell carcinoma has evolved slowly. The earlier reports of increased benefit from radiotherapy, as adjuvant to nephrectomy, were tempered by the improved survival afforded to patients using...
-
Chapter
Combination of Chemotherapy and Hormones in Prostatic Cancer
The National Prostatic Cancer Project in a four-year period has accessioned 301 patients with newly diagnosed Stage D-2 prostatic cancer into a treatment protocol comparing cyclophosphamide (Cytoxan) plus estr...
-
Chapter
Fine-Needle Aspiration of Soft-Tissue Masses in Prostatic Cancer Patients
Fine-needle aspiration cytology of soft-tissue masses can play a major role in both staging and monitoring of therapy for patients with prostatic cancer. The procedure is safe, inexpensive and easy to perform ...
-
Chapter
Criteria for Evaluating Response to Treatment in Prostatic Cancer
Better delineation of criteria for both objective and subjective responses to treatment of prostatic cancer will aid in evaluating new cytotoxic agents as well as combinations of endocrine manipulation and che...
-
Chapter
Renal Cancer — Clinical Studies in the U.S.A.
The five year survival for untreated renal cell cancer is approximately 2%. This increases to 30 – 47% following simple nephrectomy whereas the overall five year survival following radical (perifascial) nephre...
-
Chapter
Chemotherapy of Prostate Cancer: The National Prostatic Cancer Project Experience
Since 1972 the Treatment Subgroup of the National Prostatic Cancer Project has accessioned 1748 patients with various stages of prostatic cancer to 13 different treatment protocols. Seven of these protocols ha...